

RECEIVED

JUN 29 2001

Sheet 1 of 3

Form PTO-1 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DKT. NO.

BAYER 6P1

SERIAL NO.

09/776,936

APPLICANT

William J. SCOTT

FILING DATE

22 December 1998

GROUP

1614 62


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
SE	AA 3,823,161	07/09/74	Lesser			
	AB 5,130,331	07/14/92	Pascual			
	AC 4,808,588	02/28/89	King			
	AD 3,424,760	01/28/69	Helsley et al.			
	AE 3,424,761	01/28/69	Helsley et al.			
	AF 3,424,762	01/28/69	Helsley et al.			
	AG 4,071,524	01/31/78	Banitt			
	AH 4,111,683	09/05/78	Singer			
	AI 4,437,878	03/20/78	Acker et al.			
	AJ 4,643,849	02/17/87	Hirai et al.			
	AK 5,773,459	06/30/98	Tang et al.			
	AL 5,508,288	04/16/96	Forbes et al.			
	AM 4,062,861	12/13/77	Yukinaga et al.			
	AN 4,111,680	09/05/78	Yukinaga et al.			
	AO 4,116,671	09/26/78	Yukinaga et al.			
	AP 4,212,981	07/15/80	Yukinaga et al.			
	AQ 5,162,360	11/10/92	Creswell et al.			
	AR 4,514,571	04/30/85	Nakai et al.			
	AS 3,754,887	08/28/73	Brantley			
	AT 3,646,059	02/29/72	Brantley			
	AU 5,696,138	12/9/97	Olesen et al.			
	AV 5,780,483	7/14/98	Widdowson et al.			
	AW 4,405,644	9/20/83	Kabbe et al.			
	AX 4,473,579	9/25/84	Devries et al.			
	AY 4,526,997	7/2/85	O'Doherty et al.			
	AZ 4,468,380	8/28/84	O'Doherty et al.			
	BA 4,623,662	11/18/86	De Vries			
	BB 4,985,449	1/15/91	Haga et al.			
	BC 5,312,820	5/17/94	Ashton et al.			
	BD 4,410,697	10/18/83	Török et al.			
	BE 4,001,256	1/4/97	Callahan et al.			
	BF 5,399,566	3/21/95	Katano et al.			
	BG 5,500,424	3/19/96	Nagamine et al.			
	BH 5,597,719	1/28/97	Freed et al.			

Not considered 6/15/98



RECEIVED

09/17/02, 9/20/02
TECH CENTER 1600/2900

SE	BI	4,183,854	7/80	Crossley			
	BJ	3,828,804	8/74	Broad et al.			
	BK	4,740,520	4/88	Hallenbach et al.			
	BL	5,319,099	6/7/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
SE	BM	EP 335156	03/11/89	European			X
	BN	EP 459887	05/28/91	European			X
	BO	EP 371876	11/28/89	European			X
	BP	93/24458	12/9/93	WO		X	
	BQ	2,146,707	10/12/95	Canada		X	
	BR	96/40673	12/19/96	WO		X	
	BS	94/14801	07/07/94	WO		X	
	BT	94/25012	11/10/94	WO		X	
	BU	1,590,870	06/10/81	England		X	
	BV	93/18028	09/16/93	WO		X	
	BW	94/18170	08/18/94	WO		X	
	BX	DE 3305866 A1	02/19/83	Germany			X
	BY	95/02591	01/26/95	WO		X	
	BZ	95/13067	05/18/95	WO		X	
	CA	95/07922	03/23/95	WO		X	
	CB	95/31451	11/23/95	WO		X	
	CC	A1 96/40675	12/19/96	WO		X	
	CD	JP 53 086033	7/29/78	Japan			
	CE	JP 51 063170	1/6/76	Japan			
	CF	97/49400	12/31/97	WO			
	CG	97/49399	12/31/97	WO			
	CH	96/40673	12/19/96	WO			
	CI	99/00357	1/7/99	WO			
	CJ	97/45400	12/4/97	WO			
	CK	96/02112	3/8/90	WO			
	CL	99/00370	1/7/99	WO			
	CM	97/29743	8/21/97	WO			
	CN	98/22432	5/28/98	WO			
	CO	96/25157 A1	8/22/96	WO			
	CP	97/40028 A1	10/30/97	WO			

All cases done by 5/16/02



09/776, 936

ORIGINAL DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
	CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
	CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
	CT	"Beilstein number" Collection, 28 pages.
	CU	"Beilstein Collection," 4 pages.
	CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
	CX	Substructure Search, pages 1-30.
	CY	Derwent World Patents Index Search, pages 20-26.
	CZ	Abstract of EP 116,932.
	DA	Abstract of EP 676,395.
	DB	Abstract of EP 202,538.
	DC	Abstract of EP 16,371.
	DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway" TIBS 19; July 1994; pp. 279-2823.
	DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
	DF	Audia, James E., et al., "Potent, Selective Tetrahydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
	DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
	DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
	DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
	DJ	G. Daum, et al., "The ins and outs of Raf Kinases,," TIBS 19, November 1994, pages 474-80.
	DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
	DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
	DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
	DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
	DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
	DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
	DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
	DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
	DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
4	DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.

~~Not cash due \$ 5/16/02~~

(19)



09/776,936

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
SK	DU	5,059,614	10/22/91	Lepage et al.		
	DV	3,743,498	7/3/73	Brantley		
	DW	3,547,940	12/15/70	Brantley		
	DX	5,432,468	7/11/95	Moriyama et al.		
	DY	1,742,156	12/12/91	Fitzky		
	DZ	2,046,375	7/36	Goldstein et al.		
	EA	2,093,265	9/19/37	Coffby et al.		
	EB	2,288,422	6/42	Rohm		
	EC	2,683,082	7/54	Hill et al.		
	ED	2,745,874	5/56	Schetty et al.		
	EF	2,781,330	2/57	Downey		
	EG	2,867,659	1/59	Model et al.		
	EH	2,877,268	3/59	Applegate et al.		
	EI	2,960,488	11/60	Tamblyn et al.		
	EJ	3,689,550	9/72	Schellenbaum et al.		
	EK	3,860,645	1/95	Nikawitz		
	EL	5,423,905	6/95	Fringeli		
	EM	2,973,386	2/61	Weldon		
	EN	3,230,141	1/66	Frick et al.		
	EO	4,863,924	9/89	Haga et al.		
	EP	4,511,571	4/85	Böger et al.		
	EQ	4,173,638	11/79	Nishiyama et al.		
	ER	4,173,637	11/79	Nishiyama et al.		
	ES	4,820,871	4/89	Kissener et al.		
	ET	4,983,605	1/91	Kondo et al.		
	EU	5,098,907	3/92	Kondo et al.		
	EV	5,036,072	7/91	Nakajama et al.		
	EW	5,470,882	11/95	Dixon et al.		
	EX	5,429,918	7/95	Seto et al.		
	EY	3,151,023	9/64	Martin		
	EZ	3,200,035	8/65	Martin et al.		
	FA	5,807,891	9/15/98	Bold et al.		
	FB	4,009,847	3/1/77	Aldrich et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	N
SK	FC	95/33458	12/14/95	WO			
	FD	0 771 333	3/57	Great Britain			
	FE	0 921 682	3/63	Great Britain			
	FF	0 253 997	2/88	East Germany			
	FG	0 405 233	1/91	Europe			
	FH	1 457 172	9/66	France			

FI	0 487 014	12/29	Germany
FJ	0 511 468	10/30	Germany
FK	0 523 437	5/31	Germany
FL	44 2569	2/69	Japan
FM	55 98152	7/80	Japan
FN	94 22807	10/94	WIPO
FO	3 532 47	3/91	Japan
FP	0 828 231	10/56	Great Britain
FQ	50-149668	11/75	Japan
FR	55-162772	12/80	Japan
FS	60-76072	6/75	Japan
FT	51-80862	7/76	Japan
FU	50-77375	6/75	Japan
FV	55-124763	9/80	Japan
FW	0 502 504 A1	9/92	Europe

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

FX	Tarzia, G. et al. "Whythesis and anti-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
FY	Abstract WO 9922103 , Hedge 28 May 1998
FZ	

Examiner	S. J. [Signature]	Date Considered	4/18/03
----------	-------------------	-----------------	---------

09/776,936

Form PTO 1442 (Modified)

Q I P E JC82
JUN 28 2001
Q I P E
JUN 28 2001

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT

ATTY DOCKET NO.
Bayer 6P1

SERIAL NO.
09/776,936

APPLICANT
William J. SCOTT

FILING DATE
22 December 1998

GROUP
1814)621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
SE	AA	5,429,918	4 July 1995	SETO ET AL.			
	AB	5,814,646	9/29/1998	HEINZ			
	AC	4,042,372	8/16/1977	HARPER			
	AD	3,990,879	11/9/1976	SOPER			
	AE	5,185,358	2/09/1993	CRESWELL			
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
SE	AO	16371	3/5/80	EP		
	AP	676395	7/17/1996	EP		
	AQ	2436179	2/6/1975	DE		
	AR	242666	10/28/1987	EP		
	AS	97/32111	7/01/1999	WO		
	AT	99/32455	7/01/1999	WO		
	AU	99/24398	5/20/1999	WO		
	AV	98/52559	11/26/1998	WO		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

SE	AW	Kubo, Hiroshi et al: "herbicide activity..." J. Agr. Food Chem, (1970), 18(1), 60-5
SE	AX	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo[3,2-a]-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
SE	AY	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), 339-50
SE	AZ	Grant, A.M et al.: "Hypotensive thiadiazoles" J.Med. Chem. (1972), 15(10), 1082-4

Examiner *S. Kumar* Date Considered *4/18/03*

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(22)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. Bayer 6P1		SERIAL NO. 09/776,936	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT William J. SCOTT			
FILING DATE 22 December 1998				GROUP 1614) 62)			

OIPE
JUN 28 2001
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
SC	AA	5,698,581	12/16/97	KLEEMANN ET AL.			
	AB	4,760,063	07/26/88	HALLENBACH ET AL.			
	AC	4,240,820	12/23/80	DICKORE ET AL.			
	AD	5,908,865	6/1/1999	DOI ET AL.			
	AE	6,080,763	6/27/2000	REGAN ET AL.			
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
SC	AO	DE 35 29 747 A1	8/20/85	Germany	
	AP	DE 35 40 377 A1	11/14/85	Germany	
	AQ	00/17175	09/16/99	WO	
	AR	99/23091	5/14/1999	WO	
	AS	98/22103	5/28/1998	WO	
	AT	00/43384	7/27/2000	WO	
	AU	00/55152	9/21/2000	WO	
	AV	00/55139	9/21/2000	WO	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)	
SC	AW Abstract of EP 676,395 (U.S. equivalent 5,698,581)
SC	AX Abstract of EP 4931 (U.S. equivalent 4,240,820)
SC	AY Abstract of EP 116,932
SC	AZ Abstract of EP 202,538

Examiner S. K. Murr	Date Considered 4/18/03
--	--

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

ATTY DOCKET NO.
BAYER-6P1

SERIAL NO.
09/776,936

APPLICANT
William J. SCOTT

FILING DATE
22 December 1998

GROUP
1614 / 621

LIST OF REFERENCES SUBMITTED BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
gt	AA	6,093,742	7/25/00	SALITURO			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
gt	AO	97/30992	8/28/1997	WO		
	AP	97/17329	8/26/1998	WO		
	AQ	860433	8/26/1998	EP		
	AR	425443	10/19/1990	EP		
	AS	99/32437	7/1/1999	WO		
	AT					
	AU					
	AV					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)


gt	AW	Murata et al. Chemical and Pharmaceutical Bulletin, vol. 22, 1974 pp. 1212-3
	AX	Garcia-Lopez et al. Journal of the American Chemical Society, vol 1978, 1978, pp. 438-7
	AY	English abstract EP425443
	AZ	English Abstract WO9932437

Examiner S. K. **Date Considered** 9/18/03

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(24)



 Please type a plus sign (+) inside this box 

TECHNOLOGY CENTER 1600/2910

RECEIVED

APR 04 2002

PTO/SB/08A (08-00)
 Approved for use through 10/31/2002. OMB 05-00031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/776,936
		Filing Date	December 22, 1998
		First Named Inventor	Scott MILLER et al.
		Group Art Unit	1621
		Examiner Name	Kumar, S.
Sheet 1 of 3	Attorney Docket Number	BAYER 6 P1	

Attached
 per 15

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SC		5,965,573		Petrie et al.	10-12-99	
		6,218,539 B1		Widdowson	4-17-01	
		6,242,601 B1		Breu et al.	6-5-01	
		6,004,965		Breu et al.	12-21-99	
		5,891,895		Shiraishi et al.	4-6-99	
		6,174,901 B		Mantlo et al.	1-16-01	
		2,722,544		Martin	11-1-55	
		2,649,476		Martin	8-18-53	
		6,339,045 B1		Kanno et al.	1-15-02	
		6,005,008		Widdowson et al.	12-21-99	
		6,180,675 B1		Widdowson et al.	1-30-01	
		2,797,214		Werner Bossard	6-25-57	
		6,211,373 B1		Widdowson et al.	4-3-01	
		5,773,459		Tang et al.	6-30-98	
		5,780,483		Widdowson	7-14-98	
		6,133,319		Widdowson	10-17-00	
		5,886,044		Widdowson et al.	8-23-00 3/1499	
		6,020,345		Vacher et al.	2-1-00	
		6,262,113 B1		Widdowson et al.	7-17-01	
		6,333,341 B1		Mantlo et al.	12-25-01	
		6,271,261 B1		Widdowson	8-7-01	

Attached

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
SC		EP	0116932			8-29-84		
SC		WO	98/17267			4-30-98		

Examiner Signature	S. Kumar	Date Considered	4/18/03
--------------------	----------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

(14)



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott MILLER et al.
Group Art Unit	1621
Examiner Name	Kumar, S.
Attorney Docket Number	BAYER 6 P1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K		Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980	
		Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryoza et al., November 15, 1982	
		Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981	
		Caplus 84:43857, Abstract JP 58021626, Maeda Ryoza et al., May 2, 1983	

Examiner Signature	S. Kumar	Date Considered	4/18/03
-----------------------	----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/vb

K:\Bayer\6p1\pto 1449.dot

(12)

